References
- Adamia S, Maxwell CA, Pilarski LM. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 3–14.
- Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992; 89: 12160–12164.
- Tolg C, Hofmann M, Herrlich P, Ponta H. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res 1993; 21: 1225–1229.
- Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303–1313.
- Messadi DV, Bertolami CN. CD44 and hyaluronan expression inhuman cutaneous scar fibroblasts. Am J Pathol 1993; 142: 1041–1049.
- Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992; 116: 817–825.
- Toyama-Sorimachi N, Sorimachi H, Tobita Y et al. A novel ligandfor CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J Biol Chem 1995; 270: 7437–7444.
- Hidalgo A, Robledo MM, Teixido J. CD44-mediated hematopoie-tic progenitor cell adhesion and its complex role in myelopoiesis. J Hematother Stem Cell Res 2002; 11: 539–547.
- Schwarzler C, Oliferenko S, Gunthert U. Variant isoforms of CD44 are required in early thymocyte development. Eur J Immunol 2001; 31: 2997–3005.
- Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T, Kincade PW. Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med 1990; 171: 477–488.
- Thomas L, Byers HR, Vink J, Stamenkovic I. CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol 1992; 118: 971–977.
- Yokota A, Ishii G, Sugaya Y, Nishimura M, Saito Y, Harigaya K. Expression of exon v6-containing CD44 isoforms is related to poor prognosis of acute myelocytic leukemia. Hematol Oncol 1998; 16: 131–141.
- Denning SM, Le PT, Singer KH, Haynes BF. Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol 1990; 144: 7–15.
- McKee CM, Lowenstein CJ, Horton MR et al. Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor kappaB-dependent mechanism. J Biol Chem 1997; 272: 8013–8018.
- Galandrini R, Albi N, Tripodi G et al. Antibodies to CD44 trigger effector functions of human T cell clones. J Immunol 1993; 150: 4225–4235.
- Pericle F, Sconocchia G, Titus JA, Segal DM. CD44 is a cytotoxic triggering molecule on human polymorphonuclear cells. J Immunol 1996; 157: 4657–4663.
- Sconocchia G, Titus JA, Segal DM. Signaling pathways regulating CD44-dependent cytolysis in natural killer cells. Blood 1997; 90: 716–725.
- Takahashi T, Nieda M, Koezuka Yet al. Analysis of human V alpha24+ CD4+ NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000; 164: 4458–4464.
- Webb DS, Shimizu Y, van Seventer GA, Shaw S, Gerrard TL. LFA-3, CD44, and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 1990; 249: 1295–1297.
- Hodge-Dufour J, Noble PW, Horton MR et al. Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. J Immunol 1997; 159: 2492–2500.
- Rafi A, Nagarkatti M, Nagarkatti PS. Hyaluronate-CD44 inter-actions can induce murine B-cell activation. Blood 1997; 89: 2901–2908.
- Ilangumaran S, Briol A, Hoessli DC. CD44 selectively associates with active Src family protein tyrosine kinases Lck and Fyn in glycosphingolipid-rich plasma membrane domains of human peripheral blood lymphocytes. Blood 1998; 91: 3901–3908.
- Taher TE, Smit L, Griffioen AW, Schilder-Tol EJ, Borst J, Pals ST. Signaling through CD44 is mediated by tyrosine kinases. Association with p561ck in T lymphocytes. J Biol Chem 1996; 271: 2863–2867.
- Kataoka T, Shinohara N, Takayama H et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996; 156: 3678–3686.
- Richards JD, Dave SH, Chou CH, Mamchak AA, DeFranco AL. Inhibition of the MEK/ERK signaling pathway blocks a subset of B cell responses to antigen. J Immunol 2001; 166: 3855–3864.
- Galandrini R, Piccoli M, Frati L, Santoni A. Tyrosine kinase-dependent activation of human NK cell functions upon triggering through CD44 receptor. Eur J Immunol 1996; 26: 2807–2811.